Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000079

Drug Information
NameCC-401
CompanyCelgene
IndicationMyeloid LeukemiaDiscontinued in Phase I    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14
-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(
H,25,26)(H,23,24,27)
InChIKeyXDJCLCLBSGGNKS-UHFFFAOYSA-N
Canonical SMILESC1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5    
Therapeutic ClassAntineoplastic Agents
PubChem Compound IDCID 10430360.
ClinicalTrials.govNCT00126893;
TargetStress-activated protein kinase JNK1Inhibitor[1][2]
Ref 1Blockade of the c-Jun amino terminal kinase prevents crescent formation and halts established anti-GBM glomerulonephritis in the rat. Lab Invest. 2009 Apr;89(4):470-84. Epub 2009 Feb 2. To Reference
Ref 2A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int. 2007 Sep;72(6):698-708. Epub 2007 Jun 27. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543